article thumbnail

Reports Document FDA Review Delays: What Drugmakers Should Know Now

FDA Law Blog: Biosimilars

Some regulatory actions or inactions like the three cited in the WSJ article may not be attributable to anything other than the machinations of a large agency and are of the sort that have plagued clients for years.

article thumbnail

AI Act: data governance and compliance strategy implications in Pharma

European Pharmaceutical Review

This article traces the compliance journey, from initial industry responses to the AI Act, through data‑sharing protocols, merger due‑diligence considerations, infrastructure investments, internal governance structures and, finally, the strategic advantages of Europe’s cohesive regulatory framework.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

FDA’s CRLs reveal 74% of applications rejected for quality, manufacturing issues

Pharma Manufacturing

Out of 202 Complete Response Letters issued between 2020 and 2024, 150 involved quality/manufacturing issues, according to the regulator’s newly released documents.

article thumbnail

Why Google Patents Is Not a Good Solution to Identify Drug Patents

Drug Patent Watch

This article explores the limitations of Google Patents in this context and suggests alternative approaches. Understanding Google Patents Google Patents is a search engine that allows users to search the full text of patent documents from around the world.

article thumbnail

Episode 1051: A Pharmacy-Driven Rapid Bacteremia Response Program

Pharmacy Joe

The article in this episode is a selection from my Hospital Pharmacy Academy’s weekly literature digest. In the first year after implementation over 2000 results were called to the pharmacy and about one-third resulted in the pharmacist ordering an antimicrobial.

article thumbnail

Episode 1046: PPI Stewardship Is Especially Important In Patients With CKD

Pharmacy Joe

While PPI-related adverse effects are well documented in the general population, evidence that describes these adverse effects in patients with chronic kidney disease is limited. The article in this episode is a selection from my Hospital Pharmacy Academy’s weekly literature digest.

article thumbnail

Investment Banking Trends: AI, US Fed rates, and private credit with Gaurav Bhasin

Fuld & Company Blog

Increasing due diligence efficiencies: Leveraging NLP and Gen-AI models to examine large volumes of documents in a data room for specific items of interest, reducing costs and analysis time of due diligence teams. These can be powerful tools for investment banking support teams to improve transactional processes.